Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances

por Deng, Yilun, Reyes, Ryan M, Zhang, Chenghao, Conejo-Garcia, José, Curiel, Tyler J.
Publicado 2021

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

por Reyes, Ryan M, Zhang, Chenghao, Deng, Yilun, Ji, Niannian, Mukherjee, Neelam, Padron, Alvaro S, Clark, Curtis A, Svatek, Robert S, Curiel, Tyler J
Publicado 2021

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice

por Garcia, Myrna G., Deng, Yilun, Murray, Clare, Reyes, Ryan M, Padron, Alvaro, Bai, Haiyan, Kancharla, Aravind, Gupta, Harshita, Shen-Orr, Shai, Curiel, Tyler J.
Publicado 2022

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

por Ji, Niannian, Mukherjee, Neelam, Reyes, Ryan M, Gelfond, Jonathan, Javors, Martin, Meeks, Joshua J., McConkey, David J, Shu, Zhen-Ju, Ramamurthy, Chethan, Dennett, Ryan, Curiel, Tyler J, Svatek, Robert S
Publicado 2021

Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy

por Zhang, Deyi, Reyes, Ryan M., Osta, Erica, Kari, Suresh, Gupta, Harshita B., Padron, Alvaro S., Kornepati, Anand V. R., Kancharla, Aravind, Sun, Xiujie, Deng, Yilun, Wu, Bogang, Vadlamudi, Ratna, Li, Rong, Svatek, Robert S., Curiel, Tyler J.
Publicado 2021